Aardvark Therapeutics Announces Voluntary Pause Of The Phase 3 HERO And OLE Trials Evaluating ARD-101 For The Treatment Of Hyperphagia In Individuals With Prader-Willi Syndrome, Further Guidance On The Program Expected In Q2 2026

Aardvark Therapeutics has announced a voluntary pause of the Phase 3 HERO and OLE trials for ARD-101, aimed at treating hyperphagia in individuals with Prader-Willi Syndrome, with further guidance expected in Q2 2026. The ARD-201 obesity program is also on hold pending developments with ARD-101. As of December 31, 2025, the company reported $110.0 million in cash and short-term investments, which is projected to support operations into the second quarter of 2027.